or Try an Advanced Search...

    Genentech Stocks List

    Symbol Grade Name % Change
    ADPT D Adaptive Biotechnologies Corporation -2.96
    ASND D Ascendis Pharma A/S -1.37
    BIIB D Biogen Idec Inc. 0.23
    CRIS D Curis, Inc. -6.35
    EXEL F Exelixis, Inc. -1.51
    KA F Kineta, Inc. -7.19
    LXRX F Lexicon Pharmaceuticals, Inc. -3.80
    OTLK F Outlook Therapeutics, Inc. 6.14
    SGMO D Sangamo BioSciences, Inc. 6.72
    SNDX D Syndax Pharmaceuticals, Inc. -3.01
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Biotechnology Life Sciences Cancer Drug Discovery Medicine Monoclonal Antibodies Biopharmaceutical Breast Cancer Cancer Cell Diabetes Disease Hemophilia Lung Cancer Lymphoma Monoclonal Antibody Progressive Protein Kinase Inhibitor Solid Tumors Specialty Drugs Treatment Of Breast Cancer

    Related ETFs - A few ETFs which own one or more of the above listed Genentech stocks.

    Symbol Grade Name Weight
    MEDI D Harbor Health Care ETF 16.82
    BBP C BioShares Biotechnology Products Fund 8.59
    BIS F ProShares UltraShort Nasdaq Biotechnology 8.04
    PBE C PowerShares Dynamic Biotech & Genome 7.94
    FBT C First Trust Amex Biotech Index Fund 6.8
    View all Genentech ETFs...
    Compare ETFs
    Compare MEDI to BIS Compare MEDI to FBT Compare PBE to FBT

        Genentech Stocks Recent News

        Date Stock Title
        May 17 BIIB Ionis, Biogen Down on Ending Development of ALS Drug
        May 17 OTLK Q2 2024 Outlook Therapeutics Inc Earnings Call
        May 16 OTLK Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript
        May 16 ADPT The Agency by AGI Denim Elevates Adaptive Denim
        May 16 BIIB Biogen also drops collaboration with Ionis on Angelman syndrome candidate
        May 16 BIIB Biogen and Ionis drop ALS candidate after trial setback
        May 16 BIIB Biogen, Ionis shelve ALS drug following study failure
        May 16 BIIB REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
        May 16 BIIB Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
        May 16 BIIB Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
        May 15 OTLK Outlook Therapeutics reports Q2 results
        May 15 KA Kineta GAAP EPS of -$0.89
        May 15 OTLK Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
        May 15 SNDX Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
        May 15 KA Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
        May 15 ASND FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
        May 15 BIIB Eisai projects major growth for Alzheimer's therapy Leqembi
        May 15 BIIB Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
        May 15 ASND FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
        May 15 BIIB Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Biotechnology Life Sciences Cancer Drug Discovery Medicine Monoclonal Antibodies Biopharmaceutical Breast Cancer Cancer Cell Diabetes Disease Hemophilia Lung Cancer Lymphoma Monoclonal Antibody Progressive Protein Kinase Inhibitor Solid Tumors Specialty Drugs Treatment Of Breast Cancer
        Genentech

        Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche.As of September 2017, Genentech employed 15,064 people.

        More about Genentech
        Browse All Tags